Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$472.51K-$472.51KN/M vs Q3 2024 EPS Diluted-$0.04-$0.04N/M vs Q3 2024 Operating Income-$527,902N/M Operating Cash Flowderived-$445,963N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end